Promising breast cancer combo trial for elderly pulled before start
NCT ID NCT05664893
First seen Apr 20, 2026 · Last updated May 11, 2026 · Updated 3 times
Summary
This study aimed to test the safety and effectiveness of adding the drug ribociclib to standard hormone therapy and radiation for women aged 70 and older with a certain type of breast cancer. The goal was to control the disease without surgery. However, the trial was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 NEGATIVE BREAST CANCER NOT IMMEDIATELY OPERATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.